Clinical Trial Update: First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

First-in-human dose-escalation study of SAR440234 in acute leukemia and myelodysplastic syndrome was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• SAR440234

Snippet

Sponsor: Sanofi | Conditions: Leukaemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-04-07